Safety, pharmacokinetics and pharmacodynamics of multiple‐dose noiiglutide ( <scp>SHR20004</scp> ), a novel <scp>GLP</scp> ‐1 receptor agonist, in Chinese obese subjects without diabetes mellitus
Daily administration of noiiglutide using a titration method was well tolerated by Chinese obese participants without DM and showed potential therapeutic effect for weight loss.
Authors
- Mingli Wang (ORCID: https://orcid.org/0000-0002-7412-4933)
- Fan Jiang (ORCID: https://orcid.org/0000-0001-9466-2192)
- Qian Chen (ORCID: https://orcid.org/0000-0001-9834-6912)
- Jingying Jia
- Hongjie Qian
- Chan Sun (ORCID: https://orcid.org/0009-0004-5211-9393)
- Yang Zou (ORCID: https://orcid.org/0000-0003-0887-7096)
- Chunyang Zhao (ORCID: https://orcid.org/0009-0004-4351-9336)
- Chen Yu
- Hong Chen (ORCID: https://orcid.org/0000-0003-2606-0039)
Institutions
- Fudan University (CN)
- Shanghai Xuhui Central Hospital (CN)
- Jiangsu Hengrui Medicine (China) (CN)
- Shanghai Clinical Research Center (CN)
Publication Details
- Journal
- Diabetes Obesity and Metabolism
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1111/dom.16080
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 0.00